Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. - Wikidata - wikimedia - TriplyDB

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.

http://www.wikidata.org/entity/Q34333402

about

Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates Prospects for developing an effective particle-mediated DNA vaccine against influenza.Resistance to simian immunodeficiency virus low dose rectal challenge is associated with higher constitutive TRIM5α expression in PBMC YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.Simian immunodeficiency virus infection alters chemokine networks in lung tissues of cynomolgus macaques: association with Pneumocystis carinii infection.Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis.Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Restricted SIV replication in rhesus macaque lung tissues during the acute phase of infection Particle-mediated DNA vaccine delivery to the skin.Mucosal AIDS vaccines: current status and future directions.Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.Epidermal delivery of protein and DNA vaccines.HIV vaccine design: insights from live attenuated SIV vaccines.Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge Systemic and brain macrophage infections in relation to the development of simian immunodeficiency virus encephalitis.Effect of early anti-retroviral therapy on the pathogenic changes in mucosal tissues of SIV infected rhesus macaques.Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis.Simian immunodeficiency virus infection potently modulates chemokine networks and immune environments in hilar lymph nodes of cynomolgus macaques Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.Patterns of feline immunodeficiency virus multiple infection and genome divergence in a free-ranging population of African lions.DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.Mucosal vaccine delivery: Current state and a pediatric perspective Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

P2860

Q24795604-8DC81F47-B9E0-42C7-B523-364C22D6552B Q28481573-ECFF975F-7598-4B8C-93B1-E006ACEA6053 Q28751705-2F95683F-8BDB-4BCC-BA27-8BC331FFE42C Q30380300-28429A6D-6E51-482E-B7F9-F8603BCC3429 Q30579576-15A3973C-1FAF-4F41-BAF1-34BB06EC67F3 Q33343967-81C1F647-477C-45DE-86E1-7C3BDE6F98F0 Q33604583-924C29ED-6048-4766-A1A3-88B85B84AD20 Q33698152-4EA26E25-D562-4649-8F62-9D33DD43CBA5 Q34045678-BE6F6E0F-D2FC-4E5B-87FB-5DFB3DC6A8DD Q34086922-9FD22FE1-8BF7-441F-B378-0843E4EBC143 Q34099837-05FD6BFD-9714-410B-84D8-DB7EB1A4A849 Q34354961-9B11C744-B80E-4ACC-B71C-A7E28E7EDD61 Q34590964-9C9A1046-B8C9-48B7-AD58-957122FB6F38 Q34651604-E07C2DC4-E9BE-45B4-8F5D-873ED02CD0EA Q35182076-8C5F2B13-5C17-4D24-BF28-FE240C8AEC9E Q35789145-6ABBF2A7-92C8-4C41-A9FE-C529260C45E5 Q35790864-BD8CB8C9-A3CC-4EFA-B28D-656C56FFF425 Q35851782-137F411D-1045-49B4-A5EF-3CA8DD822E53 Q35973518-4FA34AA8-0F61-43C8-B226-C8CE6411E9C8 Q36172536-F791E2D9-66FA-4961-AD20-DE8E933DC0AD Q36316708-46C61043-4F93-4125-9D63-886B611F061D Q36343536-8F2BBD97-933B-4EB3-9A12-AA834FE6F89A Q36464264-7326397B-824D-431F-8852-132CCCFCA2A5 Q36506285-FC09E0E0-C153-4EF8-A537-4701E5F717CC Q36538907-42FC5BD2-BE07-4CCE-8BD8-0F1484C2567D Q36594100-4DBE0D0E-9A66-4B0E-ADBF-E1549327219C Q36604359-C09E30F8-115E-4F19-926A-99A80D1E19A8 Q36780136-8E16F4F3-913A-4DDE-972F-B36483C3A402 Q36819089-13E6988E-BC2E-4D3F-B2D7-D6A4EEBEE349 Q36913222-7121E0C2-2410-4332-9F27-8A20E10BDF58 Q36945005-C48BDA00-FB21-4B4E-8364-465A22EA3F8C Q36949703-802CF8F8-EAD7-4650-8541-F061D97FA71C Q36954239-72E6EF6D-6824-4B6A-96F7-D31BF8907504 Q37009095-ED311294-FAB5-4D33-B295-E83B45C4386D Q37325709-765AB174-D20E-4CB3-A7E0-B54C78C53A55 Q37464882-6BC7F149-7E6C-44D3-9285-01F5858AB6A8 Q37492531-D46B70F9-4918-4376-8B66-E5740A39DEED Q38727453-C5BE5D27-DF7F-4191-8333-FDD1C997C72F Q39699309-8EBBD364-6B90-4B99-8879-13F07710C3FC Q39748804-4E75157C-A133-40EC-A2A4-24C802093998

P2860

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.

http://www.wikidata.org/entity/Q34333402

description

2002 nî lūn-bûn

@nan

2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@ast

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@en

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@nl

type

label

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@ast

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@en

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@nl

prefLabel

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@ast

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@en

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@nl

P1433

Q34333402-3DD271C8-B565-4106-901C-8885E19CDE1B

P1476

Q34333402-18534882-93E7-4C77-AA7E-612642C23BC5

P2093

Q34333402-0381A675-82A9-4812-966F-509F268B8366

Q34333402-07536E57-EE35-43FC-8A37-2B6653F3A90A

Q34333402-19D831A5-F5F2-49D1-8F97-E52884736130

Q34333402-298B4207-9419-43DB-B2B2-37A053D18794

Q34333402-34D8803C-25AB-45E5-9F7E-5756FB6EBF21

Q34333402-4DF495A9-9A99-4C76-85F4-1027A10F7F67

Q34333402-CA211A1D-120F-49E6-9D07-10CA3E5722D4

Q34333402-DBD9E73E-D4C1-4DB3-A4D7-2AE7EE5C7545

Q34333402-E2E5C63C-F879-47BC-AAD9-A1AC2B0BE909

Q34333402-E3AD7B62-D01B-4C4B-AEB1-43669A3BEFD2

P2860

Q34333402-1DD822B6-8694-4344-9839-8A324558382E

Q34333402-22C7CFD9-F0E4-4A25-9B8E-897BABEFD31C

Q34333402-26957D2E-5400-49FF-8F38-720658C92D03

Q34333402-4211C60E-B6AF-4127-834C-55AD93AAB391

Q34333402-462E86FD-D5FC-48FA-AD54-2A5FD91B6825

Q34333402-4A33E316-5E55-47F6-95C1-A60988309453

Q34333402-500305CD-0117-4BC2-8539-500B79C29123

Q34333402-527FE889-04C6-4115-96A5-181FD42AF702

Q34333402-5489A2B3-127A-4950-873B-0DD45A9F8997

Q34333402-57629912-2B10-4BFB-ACA2-3CC3A49084C7

P304

Q34333402-1BE6352A-F41C-4817-B3A3-AB97EDC47F80

P31

Q34333402-AFB49FF9-8ADE-4D4C-B694-D0D65FCE6F55

P356

Q34333402-63180DBC-0203-4E75-91BD-C498527D3545

P407

Q34333402-E2856D23-A20D-4E78-A5B7-C827624E6646

P433

Q34333402-1AEE8A33-2BAF-415F-ADE7-55B0B70F15E8

P478

Q34333402-AA7F996B-EF7E-4A44-A29C-AFCAC59C754F

P577

Q34333402-E0A84FBE-2BCC-4D3B-9DEE-A9C01532565D

P698

Q34333402-88A07848-7A98-4993-9CC5-A9D66CA7A49D

P921

Q34333402-DF70B571-99F1-46CD-B8F4-26235177B1F0

P932

Q34333402-AEBB2C0A-6A19-4449-93F0-95696E5BF295

P356

JVI.76.7.3309-3317.2002

P1433

Journal of Virology

P1476

Induction of mucosal protectio ...... ciency virus by a DNA vaccine.

@en

P2093

Anita M Trichel

http://www.w3.org/2001/XMLSchema#string

Charles R Rinaldo

http://www.w3.org/2001/XMLSchema#string

Deborah Heydenburg Fuller

http://www.w3.org/2001/XMLSchema#string

James T Fuller

http://www.w3.org/2001/XMLSchema#string

Joel R Haynes

http://www.w3.org/2001/XMLSchema#string

Kathleen Weis

http://www.w3.org/2001/XMLSchema#string

Lawrence A Wilson

http://www.w3.org/2001/XMLSchema#string

Mary S Wu

http://www.w3.org/2001/XMLSchema#string

Michael Murphey-Corb

http://www.w3.org/2001/XMLSchema#string

Premeela A Rajakumar

http://www.w3.org/2001/XMLSchema#string

P2860

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

P304

3309-3317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.7.3309-3317.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11884556

http://www.w3.org/2001/XMLSchema#string

P921

Simian immunodeficiency virus

P932

136011

http://www.w3.org/2001/XMLSchema#string